Typical supplement doses of omega-3 fatty acids EPA and DHA do not raise the risk of atrial fibrillation, according to a meta-analysis published in the journal Circulation: Arrhythmia and Electrophysiology. The study, conducted by researchers associated with the Fatty Acid Research Institute (FARI), analyzed data from 35 randomized controlled trials covering about 115,000 subjects and found that low-dose supplementation remains safe even for patients already at high risk of cardiovascular disease.
Evaluating Omega-3 Safety Across Diverse Patient Populations
For decades, researchers have studied the effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on long-term heart health, systemic inflammation, and brain function. Most of that foundational research relied on daily doses of 1 to 1.5 grams of combined EPA and DHA, with the majority hovering around 500 milligrams per day. These lower concentrations reflected what standard consumers typically ingested using conventional soft gels.
However, positive outcomes from early trials eventually led to the development of prescription-strength fish-oil drugs purified to 90% or more EPA and DHA, usually administered at 4 grams per day. This created a heterogeneous body of research encompassing various subgroups, some healthy and others suffering from advanced disease. Within this mix, a small subset of trials pointed to a potential dose-dependent relationship between omega-3 intake and atrial fibrillation (AF) risk.
Broader Data Inclusion Changes the Risk Picture
To resolve conflicting data, authors of the new FARI study cast a wider net than previous reviews. According to the research team, their goal was to conduct a comprehensive literature review and updated meta-analysis of randomized controlled trials to better understand the link between omega-3 supplementation and AF risk. They incorporated studies from nearly 4,000 registered trials spanning the past 40 years.
Ultimately, the analysis evaluated 35 studies involving roughly 115,000 participants. Crucially, this included data from trials where no increase in AF was observed—studies that earlier, more alarmist meta-analyses had excluded. By comparing risk evaluations against both omega-3 doses and underlying cardiovascular risks, the FARI group produced a clinically meaningful interpretation of the evidence.
Did you know? Out of nearly 4,000 omega-3 studies registered over the last four decades, only eight trials previously suggested a dose-dependent link between the fatty acids and atrial fibrillation.
Dose-Dependent Findings and Clinical Reassurance
The FARI analysis demonstrated a clear dose-dependent association between omega-3 fatty acid supplementation and AF risk, but with vital distinctions for everyday consumers. Low-dose omega-3 supplementation does not appear to increase AF risk, even among patients at high cardiovascular disease risk, according to the published findings.
Even in higher-dose studies involving diseased populations where researchers observed an increased risk of developing AF, the absolute risk remained small—on the order of less than 1%. FARI founder and study co-author William S. Harris, Ph.D., emphasized that these findings offer practical clarity for both physicians and patients.
What this study does is provide clinicians with better guidance on which patients may benefit from closer monitoring when using high-dose omega-3 therapies while reassuring consumers that it is safe to consume omega-3 fatty acids from foods and dietary supplements, Harris said.
Frequently Asked Questions
Do standard omega-3 supplements increase atrial fibrillation risk?
No. According to the FARI meta-analysis published in Circulation: Arrhythmia and Electrophysiology, typical supplement-sized doses of EPA and DHA do not raise the risk of atrial fibrillation, even in patients already at high risk for cardiovascular disease.
What dosage levels were evaluated in the study?
The study reviewed 35 randomized controlled trials covering about 115,000 subjects, encompassing both standard nutritional supplement doses (typically 500 mg to 1.5 grams per day) and higher pharmaceutical-grade doses (up to 4 grams per day).
Who conducted the research?
The research was performed by investigators associated with the Fatty Acid Research Institute, led by founder and co-author William S. Harris, Ph.D.
What are your thoughts on this latest safety data for omega-3 supplements? Join the conversation by leaving a comment below, or subscribe to our newsletter for more updates on heart health and clinical nutrition research.
Worth a look